Cancer

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating…

1 year ago

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL);…

1 year ago

ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Garching / Munich, Germany, December 21, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today…

1 year ago

BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer

Designation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing…

1 year ago

CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field…

1 year ago

Physicians from American Oncology Network Selected to Present at the American Society of Hematology Annual Meeting and Exposition

The network’s physicians’ research reports were selected after a thorough peer review process. AON Physicians Present Research Reports at Annual…

1 year ago

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Media Release SYDNEY, AUSTRALIA, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),…

1 year ago

Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

AUSTIN, TX and DURHAM, NC, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “company”) (NASDAQ: STTK),…

1 year ago

Cosmos Health Enters into Definitive Agreement to Acquire Type-2 Diabetes Treatment DIABIT-IS X

CHICAGO, IL / ACCESSWIRE / December 20, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

1 year ago

Lindis Blood Care Announces Last Patient Out in Multicenter Clinical Certification Study REMOVE with CATUVAB(R) to Eliminate Tumor Cells from Surgical Blood

BERLIN, GERMANY / ACCESSWIRE / December 20, 2023 / Lindis Blood Care, a company aiming to set a new standard…

1 year ago